A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis.
Inclusion Criteria:
1. Current diagnosis of AK, with ≥4 lesions located in the same anatomical district
(within a contiguous 50 cm2 area on the face, bold scalp or forehead);
2. Female or male >18 years of age;
3. Skin type I or II according to Fitzpatrick;
4. Patient has confirmed his/her willingness to participate in this study;.
Exclusion Criteria:
1. Topical drug therapy for AK within the past 3 months or for photoaging in the last 6
months, or had lesion-directed therapy within 2 cm2 of the selected AK area during
the previous month;
2. Suitable for surgical, photodynamic or any other topical treatment in the next 6
months;
3. Subjects who suffer/ had suffered from skin cancer or show an early stage of skin
cancer or have a genetic predisposition for skin cancer;
4. Other skin disease that requires treatment with other medications in the treatment
area or in the distance of 3 cm;
5. Immunosuppression or current treatment for cancer;
6. Clinically unstable medical condition;
7. High risk group for HIV infection or presentation of other infectious diseases
8. Presentation of contact allergies or allergies to compounds of the test substances;
9. Smoker (more than forty cigarettes per day) or heavy drinker (more than three
standard drinks per day);
10. Psychiatric disease that may interfere with follow up of study procedures;
11. Participation in other clinical trials up to 30 days prior to day 1 of the study
12. Prior treatment with study medication in the area to be treated;
13. Considered by the investigator, for any other reason, to be an unsuitable candidate
for the study.